Antipsychotic-induced elevation of creatine kinase: A systematic review of the literature and recommendations for the clinical practice

Psychopharmacology

Volumn 231, Issue 22, 2014, Pages 4255-4270

  Laoutidis, Zacharias G ^a   Kioulos, Kanellos T ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antipsychotics; Creatine kinase; Neuroleptics; Rhabdomyolysis

Indexed keywords

AMISULPRIDE; BICARBONATE; CLOZAPINE; CREATINE KINASE; CREATINE KINASE MM; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MELPERONE; MYOGLOBIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; ANTISOCIAL PERSONALITY DISORDER; BIPOLAR DISORDER; BORDERLINE STATE; COMPARTMENT SYNDROME; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DELUSIONAL DISORDER; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DIURESIS; DRUG DOSE REDUCTION; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTHYMIA; EXERCISE; GENERALIZED ANXIETY DISORDER; HEMODIALYSIS; HUMAN; INCONTINENCE; LETHARGY; MAJOR DEPRESSION; MENTAL DEFICIENCY; MUSCLE RESECTION; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX RATIO; SYSTEMATIC REVIEW; TACHYCARDIA; TACHYPNEA; UNSPECIFIED SIDE EFFECT; ADULT; AGED; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CREATINE KINASE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84922079754     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3764-2     Document Type: Review

References (61)

1. Adityanjee (1991) The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 158:706-707
2. Agarkar S (2011) Elevated creatine kinase levels with second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 23(3):E49-E50. doi: 10.1176/appi.neuropsych.23.3.E49
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edn. American Psychiatric Association, Washington DC
4. Apikoglu Rabus S, Izzettin F, Rabus M, Bilici M (2006) Severe creatine kinase increase during quetiapine and mirtazapine treatment. Psychopharmacology (Berl) 185(2):263-264
5. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633. doi: 10.1002/14651858.CD006633.pub2
6. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11:CD006625. doi: 10.1002/14651858.CD006625.pub3
7. Baumgart U, Schmid R, Spiessl H (2005) Olanzapine-induced acute rhabdomyolysis - a case report. Pharmacopsychiatry 38(1):36-37
8. Boot E, de Haan L (2000) Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berl) 150(3):347-348
9. Cavanaugh JJ, Finlayson RE (1984) Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J Clin Psychiatry 45(8):356-357
10. Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD (2008) The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med 19:568-574
11. Conley RR, Meltzer HY (2000) Adverse events related to olanzapine. J Clin Psychiatry 61(Suppl 8):26-29
12. Correll CU (2007) Acute and long-term adverse effects of antipsychotics. CNS Spectr 12(12 Suppl 21):10-14
13. De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, van Eyck D, Scheen A, Peuschkens J (2006) Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67:1889-1896
14. Deravajan S, Dursun SM (2000) Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology (Berl) 152:122
15. Flanagan RJ (2008) Side effects of clozapine and some other psychoactive drugs. Curr Drug Saf 3(2):115-122
16. Giannoglou GD, Chatzizisis YS, Misirli G (2007) The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Int Med 18:90-100
17. Giner V, Muñoz R, Redón J (2002) Risperidone severe cerivastatin-induced rhabdomyolysis. J Intern Med 251(2):177-178
18. Harper CR, Jacobson TA (2007) The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 18:401-408
19. Himmerich H, Ehrlinger M, Hackenberg M, Löhr B, Nickel T (2006) Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. J Clin Psychopharmacol 26(6):676-677
20. Hoshi S, Itoh A, Kato S, Suzuki K, Kawamura S, Orikasa S (1999) Severe rhabdomyolysis as a complication of high-dose chemotherapy in a patient with advanced testicular cancer. Int J Urol 6(1):56-58
21. Karre PR, Gujral J, Rodriguez E (2009) Rhabdomyolysis with erratic serum creatinin phosphokinase levels: intramuscular injection of haloperidol decanoate. BMJ Case Rep. doi: 10.1136/bcr.06.2009.1931
22. Keshavan MS, Stecker J, Kambhampati RK (1994) Creatine kinase elevations with clozapine. Br J Psychiatry 164(1):118-120
23. Kirson JI, McQuistion HL, Pierce DW (1995) Severe elevations in serum creatine kinase associated with clozapine. J Clin Psychopharmacol 15(4):287-288
24. Klein JP, Fiedler U, Appel H, Quante A, Jockers-Scherübl MC (2006) Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry 39(1):39-40
25. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006654.pub2
26. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD006626.pub2
27. Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H (1998) Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium dependent potassium permeability of cell membranes. Clin Neuropharmacol 21(4):262-264
28. Lazarus AL, Toglia JU (1985) Fatal myoglobinuric renal failure in a patient with tardive dyskinesia. Neurology 35(7):1055-1057
29. Marcus EL, Vass A, Zislin J (1999) Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 33(6):697-700
30. Marinella MA (1997) Rhabdomyolysis associated with haloperidol without evidence of NMS. Ann Pharmacother 31(7-8):927-928
31. Marsh SJ, Dolson GM (1995) Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. Ren Fail 17(4):475-478
32. Martí-Bonmatí E, San Valero-Carcelén E, Ortega-García MP, Rubini-Puig R (2003) Olanzapine elevation of serum creatine kinase. J Clin Psychiatry 64(4):483-484
33. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25(11):2822-2835
34. Marzetti E, Bocchino L, Teramo S, Scudieri G, Aulisa AG (2012) Rhabdomyolysis in a patient on aripiprazole with traumatic hip prosthesis luxation. J Neuropsychiatry Clin Neurosci 24(4):E40-E41. doi: 10.1176/appi.neuropsych.11110328
35. McMahon GM, Zeng X, Walkar SS (2013) A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med. doi: 10.1001/jamainternmed.2013.9774
36. Meltzer HY (1968) Creatine kinase and aldolase in serum: abnormality common to acute psychoses. Science 159:1368-1370
37. Meltzer HY (1969) Muscle enzyme release in the acute psychoses. Arch Gen Psychiatry 21:102-112
38. Meltzer HY (2000) Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 150(3):349-350
39. Meltzer HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15(4):395-405
40. Mohr WK, Petti TA, Mohr BD (2003) Adverse effects associated with physical restraint. Can J Psychiatry 48(5):330-337
41. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reaction. Clin Pharm Ther 30(2):239-245
42. Oulis P, Koulouris GC, Konstantakopoulos G, Masdrakis VG (2007) Marked elevation of creatine kinase with sertindole: a case report. Pharmacopsychiatry 40(6):295-296
43. Pearlman C, Wheadon D, Epstein S (1988) Creatine kinase elevation after neuroleptic treatment. Am J Psychiatry 145(8):1018-1019
44. Perlov E, Tebartz van Elst L, Czygan M, Bubl E, Ebert D (2005) Serum creatine kinase elevation as a possible complication of therapy with olanzapine. Naunyn Schmiedebergs Arch Pharmacol 372(2):168-169
45. Punukollu B, Rutherford H (2008) Serum creatine kinase elevation associated with olanzapine treatment. BMJ Case Rep. doi: 10.1136/bcr.06.2008.0040
46. Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A (2000) Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol 23(5):276-280
47. Robert F, Koenig M, Robert A, Boyer S, Cathébras P, Camdessanché JP (2010) Acute camptocormia induced by olanzapine: a case report. J Med Case Rep 25(4):192. doi: 10.1186/1752-1947-4-192
48. Scelsa SN, Simpson DM, McQuistion HL, Fineman A, Ault K, Reichler B (1996) Clozapine induced myotoxicity in patients with chronic psychotic disorders. Neurology 47:1518-1523
49. Scharman EJ, Troutman WG (2013) Prevention of kidney injury following rhabdomyolysis: a systematic review. Ann Pharmacother 47(1):90-105. doi: 10.1345/aph.1R215
50. Schennach-Wolff R, Stübner S, Riedel M, Müller N (2010) Extensive elevation of creatine kinase with generic clozapine, but not with Leponex. Psychiatry Res. 30;176(1):93. doi: 10.1016/j.psychres.2009.03.014
51. Shuster J (2000) Olanzapine and rhabdomyolysis. Nursing 30(9):87
52. Terao T, Matsuda S, Kojima H, Okuno K, Hori H, Kaku A, Ueda N, Etoh A (1999) Incidence and risk factors of benign creatine phosphokinase elevations in chronic psychiatric patients. Neuropsychobiology 39(4):173-180
53. Thase ME, Shostak M (1984) Rhabdomyolysis complicating rapid intramuscular neuroleptization. J Clin Psychopharmacol 4(1):46-48
54. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR (1997) Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46(10):1206-1210
55. Tseng KC, Hwang TJ (2009) Rhabdomyolysis following dose increase of clozapine and combination therapy with lithium. J Clin Psychopharmacol 29(4):398-399. doi: 10.1097/JCP.0b013e3181accfc3
56. Ursini F, Succurro E, Grembiale A, Arturi F (2010) Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur J Clin Pharmacol 66(3):321-322. doi: 10.1007/s00228-009-0773-x
57. Velasco-Montes J, Oriñuela-González I, Sanjuán-López AZ (2012) Rhabdomyolysis secondary to quetiapine. Actas Esp Psiquiatr 40(2):97-99
58. Webber MA, Mahmud W, Lightfoot JD, Shekhar A (2004) Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18(3):432-434
59. Wirshing DA (2001) Adverse effects of atypical antipsychotics. J Clin Psychiatry 62(Suppl 21):7-10
60. Wu YF, Chang KY (2011) Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia. J Neuropsychiatry Clin Neurosci 23(3):E51. doi: 10.1176/appi.neuropsych.23.3.E51
61. Zink M, Knopf U, Argiriou S, Kuwilsky A (2006) A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. J Clin Psychiatry 67(5):835